191 results about "Viral load" patented technology

The invention relates to the technical field of agricultural biology, and particularly provides a dsRNA nanocrystallization preparation for preventing and treating areca yellows as well as a preparation method and application of the dsRNA nanocrystallization preparation. Areca yellows are a destructive disease caused by areca symptomless virus type 1 (APV1), eight key target gene segments of an APV1 virus genome are screened, specific double-stranded RNA is designed, a nano-carrier is used for wrapping and delivering a dsRNA mixture obtained by transcription of the eight target gene segments, and the areca yellows are obtained by screening. And a nanocrystallization preparation for improving the environmental stability and RNA interference efficiency of the dsRNA is prepared. Experimental results show that the nanocrystallization preparation can effectively inhibit the key gene expression of APV1 virus, reduce the virus load and improve the resistance of areca catechu to yellows. The invention provides an accurate, efficient and environment-friendly biological prevention and control strategy, and has a wide agricultural application prospect.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

The invention relates to the technical field of public health information, in particular to an infectious disease transmission path generation and early warning method and system based on big data, and the method comprises the steps: collecting and cleaning multi-modal data, and obtaining a pulse event flow through neuromorphic coding; and constructing a variable order hyperedge graph in a second-level window, extracting loop life to adjust diffusion of the cellular automaton, and iteratively generating an infection prediction field. And then splicing the hyperedge graph, the prediction field and the topological fingerprint into a conditional tensor, and inputting the conditional tensor into a conditional score diffusion network to generate a future propagation event sequence. And constructing a tensor network according to the sequence, mapping the tensor network into Isin Hamiltonian, quickly selecting an intervention node through an optical delay ring reservoir and gradient descent, and issuing a ventilation or purification instruction. And after a virus load difference value before and after intervention is normalized, a tensor network, a diffusion network and a cellular automaton are synchronously updated to form a self-adaptive closed loop, so that a peak time error can be shortened, and the recall rate of a high-risk region is improved.

The invention belongs to the field of molecular biological detection, particularly relates to a quantitative composition, a kit, a method and application, and more particularly relates to an HBV quantitative composition, a kit, a method and application. The present invention provides a quantitative composition comprising a homologous vector of at least one portion of at least one of the C region, P region, X region, or S region of the HBV, and a quantitative vector, as well as primers and probes for amplifying the two vectors. The homologous vector is creatively introduced, and the concentration of nucleic acid to be detected is artificially increased, so that the stability and accuracy of PCR amplification reaction are improved. Particularly, in a sample with low virus load, the HBV can be well detected.

The invention discloses a porcine reproductive and respiratory syndrome virus mRNA (messenger Ribonucleic Acid) molecule and application thereof, and four mRNA vaccines GP35m-LNP, GP45m-LNP, GP345m-LNP and GP2345m-LNP are designed by combining structural protein GP2a, GP3, GP4 and GP5 genes of a PRRSV FJ1402 strain of NADC30-like. Mouse test results show that the GP345m-LNP can simultaneously induce strong humoral and cellular immune response, the GP2345m-LNP is secondary, and the effect is superior to that of an inactivated vaccine (only inducing humoral immunity). After immunization, the PRRSV FJ1402 strain is adopted for counteracting toxic substances, the virus load in blood and lungs of a GP345m-LNP group is obviously reduced, pathological injuries of the lungs are obviously relieved, the immune effect is superior to that of an inactivated vaccine group, and the vaccine has a relatively good application prospect.

The invention belongs to the field of molecular biological detection, particularly relates to a quantitative composition, a kit, a method and application, and more particularly relates to an HCV quantitative composition, a kit, a method and application. The present invention provides a quantitative composition comprising a homologous vector of at least one portion of at least one of at least one of the 5 'UTR region, CORE region, E1 region, E2 region, P7 region, NS2 region, NS3 region, NS4A region, NS4B region, NS5A region, NS5 region, or 3' UTR region of said HCV, and a quantitative vector, as well as primers and probes for amplifying both vectors. The homologous vector is creatively introduced, and the concentration of the sample to be detected is artificially increased, so that the stability and accuracy of PCR amplification reaction are improved. Particularly, in a sample with low virus load, the HCV can be well detected.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

The present disclosure relates to a use of Genipin-1-β-D-gentiobioside in preparation of a drug, specifically for use in a drug that treats respiratory inflammatory injury caused by coronavirus, respiratory syncytial virus, or Mycoplasma pneumoniae infection. The present disclosure has discovered that Genipin-1-β-D-gentiobioside possesses the characteristics of reducing viral load, lung index, and inflammatory cytokines in lung tissue following coronavirus infection, respiratory syncytial virus infection, or Mycoplasma pneumoniae infection. It also demonstrates a significant protective effect against death caused by coronavirus infection.

The invention discloses a fluorescent quantitative PCR (Polymerase Chain Reaction) primer probe and a kit for detecting abalone muscular dystrophy virus. The probe and the primer are designed for a highly conserved region of an AbSV genome, a real-time fluorescent PCR system is established, and the probe and the primer can be used for detection of abalone muscular dystrophy virus and quantitative analysis of virus load; the detection sensitivity is high, and 10 copies / mu L of viruses can be detected; the method is simple to operate, low in detection cost and wide in application range; the detection specificity is high, the detection speed is high, and the detection process can be completed in only 80 minutes.

The invention discloses a method, a system, equipment and a medium for detecting an HPV (human papilloma virus) DNA (deoxyribonucleic acid) integration event, and relates to the technical field of gene detection. According to the method, HPV types and virus loads (Ct values) pre-screened by qPCR are used as natural identifiers to guide grouping and mixing of samples, and HPV integrated event detection and sample tracing are synchronously realized through single sequencing. Clinical verification shows that compared with qPCR, the comprehensive sensitivity reaches 97.1%, and the cost is reduced by 60%. And a built-in targeted retest mechanism improves the reliability of a detection result. The invention provides a novel, traceable, economical and feasible solution, is used for high-throughput HPV-host genome integration feature analysis, balances cost, expandability and clinical accuracy, and provides a high-throughput and low-cost solution for HPV-related cancer screening.

The present inventors have conducted intensive studies on an antibody which controls HIV in an administration group with a high probability over a long period of time with one or several times of single-agent administration. As a result, the present inventors have surprisingly found that, when an SW-1C10 antibody, which is obtained by producing an antibody gene reported as 1C10 in silkworms, is singly administered only a few times, the viral load in the blood is suppressed to the detection limit or lower at an early stage in all of individuals to which the antibody has been administered, and moreover, the viral RNA load in the blood is maintained at the detection limit or lower for a long time of 12 weeks.

The utility model discloses an efficient low-resistance type fan pipe coil return air purification device which is provided with a purification shell, the upper side and the lower side of the purification shell are provided with a return air inlet and a return air outlet respectively, and a detachable nanofiber filter screen is installed in the purification shell. The front side wall of the purification shell is further provided with a pressure difference sensor, and a pressure tapping pipe opening high-pressure end and a pressure tapping pipe opening low-pressure end of the pressure difference sensor are connected to the return air inlet and the return air outlet respectively. An overhaul window is further formed in the front side wall of the purification shell, and an overhaul cover plate is mounted on the overhaul window; the purification device disclosed by the utility model has the main characteristics of high particulate matter purification efficiency and low wind resistance, and can be matched with a fan system to quickly improve the indoor air quality. Especially in crowded areas such as hospitals, air circulation is not good, the virus load in the air is high, and a safe breathing environment for patients, family members and medical staff can be created through positive air change of the breathing device.

The invention relates to the technical field of biological medicines, and particularly discloses application of a swine STING molecular agonist SR-717 in preparation of a pseudorabies virus infection resisting medicine. The swine STING molecular agonist SR-717 can be stably combined with swine STING protein, the promoter activity of a downstream signal molecule interferon regulatory factor 3 (IRF3) and I-type interferon (IFN beta) is enhanced, PRV replication can be remarkably inhibited, the virus load is reduced, and pathological changes of infected mouse lung, brain and other tissues are reduced. The SR-717 provided by the invention has good targeting property and immune activation ability, and is suitable for intervention treatment of porcine pseudorabies virus infection.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The present application belongs to the field of veterinary medicine, and specifically discloses a traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis, a preparation method and application thereof. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: Ephedra 12 parts, apricot kernel 12 parts, licorice 9 parts, coix seed 30 parts, forsythia 12 parts, honeysuckle 20 parts, white eupatorium 12 parts, smilax 20 parts, and purple violet 6 parts. The composition can be used for preventing and treating artificially infected IBV chicks, and can significantly improve the survival rate of chicks, alleviate the decrease in body weight growth caused by IBV, relieve clinical symptoms, reduce the viral load in trachea and kidney tissues, reduce organ pathological damage, and promote the recovery of the body. The traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis is easy to obtain, rich in resources, low in cost, safe, non-toxic and non-residual, and the preparation method is simple and suitable for large-scale production.

This invention, entitled "A Method and Application for Target Gene Quantification in qPCR Using a Quantitative Internal Standard and a Comprehensive Correction Coefficient," belongs to the field of nucleic acid detection technology. The technical problem it addresses is that existing qPCR techniques require the establishment of a standard curve using a reference sample of known concentration, increasing reagent costs and experimental complexity, and resulting in poor reproducibility. The key technical solution is to provide a method for quantitative viral load qPCR analysis of a single sample. Specifically, it provides an internal standard with a known copy number, i.e., a quantitative internal standard, and establishes a correction method. Through a systematic error compensation mechanism, it achieves accurate quantification of the target gene. This method ensures both accuracy and reproducibility while simplifying detection design in clinical applications.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.

The invention discloses application of difluoromethyl ornithine in preparation of a medicine for preventing and / or treating diseases caused by porcine circovirus type 2 infection, and belongs to the technical field of biology. It is found that difluoromethyl ornithine can efficiently inhibit infection of the porcine circovirus type 2 to host cells and mice, reduce the virus titer of the porcine circovirus type 2, inhibit expression of Cap protein of the porcine circovirus type 2, significantly reduce the virus load in mice and relieve infection symptoms. And the difluoromethyl ornithine is relatively low in cytotoxicity and has no obvious toxic and side effects on mice. The difluoromethyl ornithine can be used for preparing the medicine for resisting the porcine circovirus type 2, and a new treatment choice is provided for preventing and treating porcine circovirus type 2 infection and porcine circovirus related diseases in actual pig raising production.

The invention discloses dsRNA (double-stranded ribonucleic acid) of a targeted IPV (infectious precocity virus) NS1 gene and application of the dsRNA. The dsRNA disclosed by the invention consists of a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO.1 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO.2. The dsRNA is injected into the macrobrachium rosenbergii infected with the IPV virus, so that the load of the IPV virus can be obviously reduced by utilizing the dsRNA, and the growth inhibition of the IPV virus on the macrobrachium rosenbergii is relieved. On the basis, the dsRNA or a biological material capable of expressing the dsRNA, such as a cell or a strain capable of expressing the dsRNA, can be used for preparing a reagent for inhibiting the IPV virus, so that viral diseases caused by IPV virus infection are prevented and treated. The composition is beneficial to prevention and treatment of IPV virus related diseases, and promotes the long and stable development of the macrobrachium rosenbergii breeding industry.

The invention relates to the technical field of molecular biology, and particularly discloses a porcine bocavirus G3 gene group SYBR Green I fluorescent quantitative PCR (polymerase chain reaction) detection primer and application thereof. A synthetic primer is designed according to a highly homologous conserved region of a VP1 gene of a PBoV-G3 gene group, an SYBR Green I fluorescent quantitative PCR method for detecting PBoV-G3 is established, and the SYBR Green I fluorescent quantitative PCR method has the advantages of strong specificity, high sensitivity and good repeatability. Compared with a TaqMan probe method, the method has the advantages that no complex and expensive probe is used, and the detection cost is saved. Compared with common PCR, SYBR Green I fluorescent quantitative PCR can directly quantify the virus load without treatment after amplification, so that the possibility of pollution is reduced, and the method is more suitable for clinical detection of the porcine bocavirus G3 gene group.

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine aiming at a fever with thrombocytopenia syndrome virus (SFTSV) and application of the mRNA vaccine. According to the vaccine, Gn and Gc glycoproteins are co-expressed in vivo, and four optimized mutations are introduced at key sites: N33Q, N63Q and K288R of the Gn protein and S962A of the Gc protein. The mutation can remove glycosylation, enhance protein conformational stability and reduce Gc-mediated membrane fusion activity, thereby improving the immunogenicity and safety of the antigen. The mRNA vaccine provided by the invention can induce a neutralizing antibody with a higher level; in a mouse challenge experiment, the vaccine shows higher survival rate and lower virus load, and has an excellent protection effect. Therefore, the mRNA vaccine disclosed by the invention has a wide application prospect in the aspect of preventing the severe fever with thrombocytopenia syndrome virus.

Peptides generating antibodies to human immunodeficiency virus (HIV) post-infection were identified. Higher antibody reactivity to these peptides was associated, with lower viral load post-infection.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a respiratory syncytial virus infected mouse model. Disodium clodronate liposome with the concentration of 4ng / mL is injected into the lateral ventricle of the mouse through stereotactic positioning of the brain. 48h after injection, mouse brain tissues are taken to detect the activation state of microglial cells through immunofluorescence and WB, after it is confirmed that the microglial cells are inhibited, RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments are carried out on the mouse, and after the 5th day after virus infection, the mouse is infected by the RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments. Likewise, mouse brain tissue is taken for virus load detection, and neuropathological changes of the mouse brain tissue are observed through HE staining, immunofluorescence and TUNEL staining, so that the method can be used for constructing a research model of RSV-related nervous system diseases.

The invention provides application of Hnf4alpha or a biological material containing Hnf4alpha in preparation of a product for inhibiting bacteria and / or viruses, and belongs to the technical field of biological medicines. In-vivo and in-vitro experiments show that overexpression of the Hnf4alpha not only can effectively prevent infection of aeromonas salmonicida and grass carp hemorrhagic disease viruses, but also can remarkably inhibit co-infection of the aeromonas salmonicida and the grass carp hemorrhagic disease viruses. The bacterial or virus load after infection is obviously reduced, and the activity of cells and the survival rate of juvenile fish are improved. The invention provides a molecular target for prevention and control of bacterial infectious diseases, virus infectious diseases and mixed infectious diseases of cyprinid fishes.

A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and / or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N / mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.